Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
John-Ih Lee & Sebastian Jander. (2017) Myasthenia gravis: recent advances in immunopathology and therapy. Expert Review of Neurotherapeutics 17:3, pages 287-299.
Read now
Read now
Matthew N Meriggioli & Donald B Sanders. (2012) Muscle autoantibodies in myasthenia gravis: beyond diagnosis?. Expert Review of Clinical Immunology 8:5, pages 427-438.
Read now
Read now
Kathleen Vrolix, Judith Fraussen, Peter C. Molenaar, Mario Losen, Veerle Somers, Piet Stinissen, Marc H. De Baets & Pilar Martínez-Martínez. (2010) The auto-antigen repertoire in myasthenia gravis. Autoimmunity 43:5-6, pages 380-400.
Read now
Read now
Linda L Kusner, Henry J Kaminski & Jindrich Soltys. (2008) Effect of complement and its regulation on myasthenia gravis pathogenesis. Expert Review of Clinical Immunology 4:1, pages 43-52.
Read now
Read now
Geir Olve Skeiea, Janardan P. Pandey, Johan A. Aarli & Nils Erik Gilhus. (1997) Autoimmunity to Ryanodine Receptor and Titin in Myasthenia Gravis is Associated with GM Allotypes. Autoimmunity 26:2, pages 111-116.
Read now
Read now
Articles from other publishers (61)
Sohyeon Kim, Ki Hoon Kim, Hye Yoon Chung, Hyung Jun Park, Young-Chul Choi, Ha Young Shin & Seung Woo Kim. (2022) Anti-titin antibodies are associated with myocarditis in patients with myasthenia gravis. Journal of Neurology 270:3, pages 1457-1465.
Crossref
Crossref
Johnny S Randhawa, Lauren S Kim, Cesar Aguilar, Alexander T Phan, Hadi Abou-El-Hassan & Lisa Herring Sovory. (2023) Atypical Seropositive Striated Muscle Antibody Myasthenia Gravis Presentation With Metastatic B1 Thymoma: A Rare Case. Cureus.
Crossref
Crossref
Karl Jõgi, Liis Sabre, Merit Rosental, Alo-Rainer Leheste & Janek Vilisaar. (2022) New Onset Generalized Myasthenia Gravis Evolving Following SARS-CoV-2 Infection. COVID 2:4, pages 464-471.
Crossref
Crossref
Gyanendra Swaroop Mittal, B. Niranjan Naik & Deepak Sundriyal. (2021) Myasthenia Gravis Following Excision of a Large Thymoma. Indian Journal of Surgical Oncology 12:2, pages 446-449.
Crossref
Crossref
Gregorio Spagni, Laura Todi, Gabriele Monte, Mariagrazia Valentini, Gabriele Di Sante, Valentina Damato, Mariapaola Marino, Amelia Evoli, Francesca Lantieri & Carlo Provenzano. (2021) Human Leukocyte Antigen Class II associations in late‐onset Myasthenia Gravis. Annals of Clinical and Translational Neurology 8:3, pages 656-665.
Crossref
Crossref
Robert A. DeSimone, Sabrina EWA Racine-Brzostek & Huy P. Pham. 2020. Immunologic Concepts in Transfusion Medicine. Immunologic Concepts in Transfusion Medicine
239
249
.
Sergio Cepeda, Carolina Cantu, Stephanie Orozco, Yangming Xiao, Zoe Brown, Manpreet K. Semwal, Thomas Venables, Mark S. Anderson & Ann V. Griffith. (2018) Age-Associated Decline in Thymic B Cell Expression of Aire and Aire-Dependent Self-Antigens. Cell Reports 22:5, pages 1276-1287.
Crossref
Crossref
Isabell Cordts, Nicolas Bodart, Kathi Hartmann, Katerina Karagiorgou, John S. Tzartos, Lin Mei, Jens Reimann, Philip Van Damme, Michael H. Rivner, Alain Vigneron, Joachim Weis, Jörg B. Schulz, Socrates J. Tzartos & Kristl G. Claeys. (2017) Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. Journal of Neurology 264:6, pages 1193-1203.
Crossref
Crossref
Arnold I. Levinson & Robert P. Lisak. 2016. Manual of Molecular and Clinical Laboratory Immunology. Manual of Molecular and Clinical Laboratory Immunology
954
960
.
Lei Zhang, Junfeng Liu, Hongna Wang, Chongbo Zhao, Jiahong Lu, Jun Xue, Yong Gu, Chuanming Hao, Shanyan Lin & Chuanzheng Lv. (2014) Double filtration plasmapheresis benefits myasthenia gravis patients through an immunomodulatory action. Journal of Clinical Neuroscience 21:9, pages 1570-1574.
Crossref
Crossref
Elham Bayat & Henry J. Kaminski. 2014. Neuromuscular Disorders in Clinical Practice. Neuromuscular Disorders in Clinical Practice
69
77
.
R. Nakata, M. Motomura, T. Masuda, H. Shiraishi, M. Tokuda, T. Fukuda, T. Ando, T. Yoshimura, M. Tsujihata & A. Kawakami. (2013) Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis. European Journal of Neurology 20:9, pages 1272-1276.
Crossref
Crossref
Shin J. Oh, Marla B. Morgan, Liang Lu, Yuki Hatanaka, Shoji Hemmi, Angela Young & Gwendolyn C. Claussen. (2012) Different Characteristic Phenotypes According to Antibody in Myasthenia Gravis. Journal of Clinical Neuromuscular Disease 14:2, pages 57-65.
Crossref
Crossref
M. Michaud, J. Delrieu & L. Astudillo. (2011) Canalopathies auto-immunes. La Revue de Médecine Interne 32:12, pages 742-750.
Crossref
Crossref
Fredrik Romi. (2011) Thymoma in Myasthenia Gravis: From Diagnosis to Treatment. Autoimmune Diseases 2011, pages 1-5.
Crossref
Crossref
Nils Erik Gilhus, Michael P. Barnes & Michael BraininG. O. Skeie, S. Apostolski, A. Evoli, N. E. Gilhus, I. Illa, L. Harms, D. Hilton‐Jones, A. Melms, J. Verschuuren & H. Westgaard Horge. 2010. European Handbook of Neurological Management. European Handbook of Neurological Management
321
331
.
G. O. Skeie, S. Apostolski, A. Evoli, N. E. Gilhus, I. Illa, L. Harms, D. Hilton‐Jones, A. Melms, J. Verschuuren & H. W. Horge. (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. European Journal of Neurology 17:7, pages 893-902.
Crossref
Crossref
Jun-Feng Liu, Wei-Xin Wang, Jun Xue, Chong-Bo Zhao, Huai-Zhou You, Jia-Hong Lu & Yong Gu. (2010) Comparing the Autoantibody Levels and Clinical Efficacy of Double Filtration Plasmapheresis, Immunoadsorption, and Intravenous Immunoglobulin for the Treatment of Late-onset Myasthenia Gravis. Therapeutic Apheresis and Dialysis 14:2, pages 153-160.
Crossref
Crossref
Johan A AarliNils Erik GilhusFredrik RomiGeir Olve Skeie. (2009) Myasthenia gravis in the elderly. Aging Health 5:4, pages 561-568.
Crossref
Crossref
A. Rosen & L. Casciola-Rosen. (2009) Autoantigens in systemic autoimmunity: critical partner in pathogenesis. Journal of Internal Medicine 265:6, pages 625-631.
Crossref
Crossref
Shin J. Oh, Marla B. Morgan, Liang Lu, Yuki Hatanaka, Shoji Hemmi, Angela Young & Gwendolyn C. Claussen. (2009) Racial differences in myasthenia gravis in Alabama. Muscle & Nerve 39:3, pages 328-332.
Crossref
Crossref
K.H. Chan, R.T.F. Cheung, W. Mak & S.L. Ho. (2007) Nonthymoma early-onset- and late-onset-generalized myasthenia gravis—A retrospective hospital-based study. Clinical Neurology and Neurosurgery 109:8, pages 686-691.
Crossref
Crossref
F. Romi, J. A. Aarli & N. E. Gilhus. (2007) Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. European Journal of Neurology 14:6, pages 617-620.
Crossref
Crossref
G. O. Skeie, S. Apostolski, A. Evoli, N. E. Gilhus, I. K. Hart, L. Harms, D. Hilton-Jones, A. Melms, J. Verschuuren & H. W. Horge. (2006) Guidelines for the treatment of autoimmune neuromuscular transmission disorders. European Journal of Neurology 13:7, pages 691-699.
Crossref
Crossref
G. O. Skeie, J. A. Aarli & N. E. Gilhus. (2006) Titin and ryanodine receptor antibodies in myasthenia gravis. Acta Neurologica Scandinavica 113:s183, pages 19-23.
Crossref
Crossref
G. O. Skeie, S. Apostolski, A. Evoli, N. E. Gilhus, I. K. Hart, L. Harms, D. Hilton‐Jones, A. Melms, J. Verschuuren & H. W. Horge. 2006. European Handbook of Neurological Management. European Handbook of Neurological Management
332
343
.
Matthew N. Meriggioli & Donald B. Sanders. (2005) Advances in the Diagnosis of Neuromuscular Junction Disorders. American Journal of Physical Medicine & Rehabilitation 84:8, pages 627-638.
Crossref
Crossref
F. Romi, J. A. Aarli & N. E. Gilhus. (2005) Seronegative myasthenia gravis: disease severity and prognosis. European Journal of Neurology 12:6, pages 413-418.
Crossref
Crossref
Fredrik Romi, Einar K. Kristoffersen, Johan A. Aarli & Nils Erik Gilhus. (2005) The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. Journal of Neuroimmunology 158:1-2, pages 191-194.
Crossref
Crossref
L. Castilla-Guerra, M.C. Fernández-Moreno, M. Rodríguez-Martínez & J.M. López-Chozas. (2004) Miastenia gravis en el anciano: experiencia de un hospital comarcal en una patología emergente. Revista Española de Geriatría y Gerontología 39:4, pages 222-226.
Crossref
Crossref
Meinoshin Okumura, Mitsunori Ohta, Yukiyasu Takeuchi, Hiroyuki Shiono, Masayoshi Inoue, Kenjiro Fukuhara, Yoshihisa Kadota, Shinichiro Miyoshi, Yoshitaka Fujii & Hikaru Matsuda. (2003) The immunologic role of thymectomy in the treatment of myasthenia gravis: implication of thymus-associated B-lymphocyte subset in reduction of the anti-acetylcholine receptor antibody titer. The Journal of Thoracic and Cardiovascular Surgery 126:6, pages 1922-1928.
Crossref
Crossref
F. Romi, N. E. Gilhus, J. E. Varhaug, A. Myking & J. A. Aarli. (2003) Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. European Journal of Neurology 10:6, pages 701-706.
Crossref
Crossref
FREDRIK ROMI, NILS E. GILHUS, JAN E. VARHAUG, ANDREAS MYKING, GEIR O. SKEIE & JOHAN A. AARLI. (2003) Thymectomy and Antimuscle Antibodies in Nonthymomatous Myasthenia Gravis. Annals of the New York Academy of Sciences 998:1, pages 481-490.
Crossref
Crossref
JOHAN A. AARLI, FREDRIK ROMI, GEIR OLVE SKEIE & NILS ERIK GILHUS. (2003) Myasthenia Gravis in Individuals over 40. Annals of the New York Academy of Sciences 998:1, pages 424-431.
Crossref
Crossref
GEIR OLVE SKEIE, FREDRIK ROMI, JOHAN A. AARLI, PÅL TORE BENTSEN & NILS ERIK GILHUS. (2003) Pathogenesis of Myositis and Myasthenia Associated with Titin and Ryanodine Receptor Antibodies. Annals of the New York Academy of Sciences 998:1, pages 343-350.
Crossref
Crossref
Geir Olve Skeie, �se Mygland, Susan Treves, Nils Erik Gilhus, Johan Arild Aarli & Francesco Zorzato. (2003) Ryanodine receptor antibodies in myasthenia gravis: Epitope mapping and effect on calcium release in vitro. Muscle & Nerve 27:1, pages 81-89.
Crossref
Crossref
T. Pirronti, P. Rinaldi, A. P. Batocchi, A. Evoli, C. Di Schino & P. Marano. (2002) Thymic lesions and myasthenia gravis. Diagnosis based on mediastinal imaging and pathological findings. Acta Radiologica 43:4, pages 380-384.
Crossref
Crossref
Fredrik Romi, Lars Bø, Geir Olve Skeie, Andreas Myking, Johan A Aarli & Nils Erik Gilhus. (2002) Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. Journal of Neuroimmunology 128:1-2, pages 82-89.
Crossref
Crossref
F. Romi, N. E. Gilhus, J. E. Varhaug, A. Myking, G. O. Skeie & J. A. Aarli. (2002) Thymectomy and anti‐muscle autoantibodies in late‐onset myasthenia gravis. European Journal of Neurology 9:1, pages 55-61.
Crossref
Crossref
G.Diane Shelton. (2002) Myasthenia gravis and disorders of neuromuscular transmission. Veterinary Clinics of North America: Small Animal Practice 32:1, pages 189-206.
Crossref
Crossref
C. BuckleyJ. Newsom–DavisN. WillcoxA. Vincent. (2001) Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology 57:9, pages 1579-1582.
Crossref
Crossref
Camilla Buckley, Daniel Douek, John Newsom-Davis, Angela Vincent & Nicholas Willcox. (2001) Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Annals of Neurology 50:1, pages 64-72.
Crossref
Crossref
G.Diane Shelton, Geir O. Skeie, Philip H. Kass & Johan A. Aarli. (2001) Titin and ryanodine receptor autoantibodies in dogs with thymoma and late-onset myasthenia gravis. Veterinary Immunology and Immunopathology 78:1, pages 97-105.
Crossref
Crossref
Amelia Evoli, Anna Paola Batocchi, Cristiana Minisci, Chiara Di Schino & Pietro Tonali. (2000) Clinical Characteristics and Prognosis of Myasthenia Gravis in Older People. Journal of the American Geriatrics Society 48:11, pages 1442-1448.
Crossref
Crossref
Fredrik Romi, Geir Olve Skeie, Christian Vedeler, Johan A Aarli, Francesco Zorzato & Nils Erik Gilhus. (2000) Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. Journal of Neuroimmunology 111:1-2, pages 169-176.
Crossref
Crossref
Hou‐Chang Chiu, Wei‐Hung Chen & Jiann‐Hong Yeh. (2001) The Six Year Experience of Plasmapheresis in Patients with Myasthenia Gravis. Therapeutic Apheresis 4:4, pages 291-295.
Crossref
Crossref
James R. Seibold. (1999) Paradoxical progress in scleroderma. Current Opinion in Rheumatology 11:6, pages 489.
Crossref
Crossref
Finn E. Somnier, Geir O. Skeie, Johan A. Aarli & Werner Trojaborg. (2003) EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis. European Journal of Neurology 6:5, pages 555-563.
Crossref
Crossref
G.Diane Shelton. (1999) Acquired myasthenia gravis: what we have learned from experimental and spontaneous animal models. Veterinary Immunology and Immunopathology 69:2-4, pages 239-249.
Crossref
Crossref
G. D. Shelton. (1998) Myasthenia gravis: lessons from the past 10 years. Journal of Small Animal Practice 39:8, pages 368-372.
Crossref
Crossref
JOHAN A. AARLI, GEIR OLVE SKEIE, ASE MYGLAND & NILS ERIK GILHUS. (1998) Muscle Striation Antibodies in Myasthenia Gravis: Diagnostic and Functional Significance. Annals of the New York Academy of Sciences 841:1 MYASTHENIA GR, pages 505-515.
Crossref
Crossref
Geir Olve Skeie, Per Kristian Lunde, Ole M. Sejersted, Åse Mygland, Johan A. Aarli & Nils Erik Gilhus. (1998) Myasthenia gravis sera containing antiryanodine receptor antibodies inhibit binding of [3H]-ryanodine to sacroplasmic reticulum. Muscle & Nerve 21:3, pages 329-335.
Crossref
Crossref
Skeie, Bentsen, Freiburg, Aarli & Gilhus. (2002) Cell‐Mediated Immune Response Against Titin in Myasthenia Gravis: Evidence for the Involvement of Th1 and Th2 cells. Scandinavian Journal of Immunology 47:1, pages 76-81.
Crossref
Crossref
Evelyn Lübke, Alexandra Freiburg, Geir O Skeie, Bernhard Kolmerer, Siegfried Labeit, Johan A Aarli, Nils E Gilhus, Robert Wollmann, Manfred Wussling, J.Caspar Rüegg & Wolfgang A Linke. (1998) Striational autoantibodies in myasthenia gravis patients recognize I-band titin epitopes. Journal of Neuroimmunology 81:1-2, pages 98-108.
Crossref
Crossref
Geir Olve Skeie, Alexandra Freiburg, Bernhard Kolmerer, Siegfried Labeit, Johan A Aarli, Samuel Appiah-Boadu & Nils Erik Gilhus. (1997) Titin Transcripts in Thymomas. Journal of Autoimmunity 10:6, pages 551-557.
Crossref
Crossref
Hirokazu Okada, Kenshi Moriwaki, Souichi Sugahara, Hidetomo Nakamoto, Takeshi Hosokawa, Katsuhiko Hamaguchi & Hiromichi Suzuki. (2007) Comparative Study of Clinical Effects Between Plasma Adsorption and Double Filtration Plasmapheresis in Patients with Myasthenia Gravis. Therapeutic Apheresis 1:4, pages 343-347.
Crossref
Crossref
J. A. Aarli. (2011) Late onset myasthenia gravis. European Journal of Neurology 4:3, pages 203-209.
Crossref
Crossref
G. O. Skeie, J. A. Aarli, R. Matre, A. Freiburg & N. E. Gilhus. (2011) Titin antibody positive myasthenia gravis patients have a cellular immune response against the main immunogenic region of titin. European Journal of Neurology 4:2, pages 131-137.
Crossref
Crossref
Johan A. Aarli. 1997. Epithelial Tumors of the Thymus. Epithelial Tumors of the Thymus
265
270
.
Geir Olve Skeie, Johan A. Aarli, Roald Matre, Alexandra Freiburg & Nils Erik Gilhus. 1997. Epithelial Tumors of the Thymus. Epithelial Tumors of the Thymus
253
260
.
G.O. Skeie, E. Bartoccioni, A. Evoli, J.A. Aarli & N.E. Gilhus. (2011) Ryanodine receptor antibodies are associated with severe myasthenia gravis. European Journal of Neurology 3:2, pages 136-140.
Crossref
Crossref